These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17205537)

  • 1. Characterization of a 3;6 translocation associated with renal cell carcinoma.
    Foster RE; Abdulrahman M; Morris MR; Prigmore E; Gribble S; Ng B; Gentle D; Ready S; Weston PM; Wiesener MS; Kishida T; Yao M; Davison V; Barbero JL; Chu C; Carter NP; Latif F; Maher ER
    Genes Chromosomes Cancer; 2007 Apr; 46(4):311-7. PubMed ID: 17205537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of renal cell carcinoma-associated constitutional chromosome abnormalities by genome sequencing.
    Smith PS; Whitworth J; West H; Cook J; Gardiner C; Lim DHK; Morrison PJ; Hislop RG; Murray E; ; Tischkowitz M; Warren AY; Woodward ER; Maher ER
    Genes Chromosomes Cancer; 2020 Jun; 59(6):333-347. PubMed ID: 31943436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma.
    Poland KS; Azim M; Folsom M; Goldfarb R; Naeem R; Korch C; Drabkin HA; Gemmill RM; Plon SE
    Genes Chromosomes Cancer; 2007 Sep; 46(9):805-12. PubMed ID: 17539022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1).
    Meléndez B; Rodríguez-Perales S; Martínez-Delgado B; Otero I; Robledo M; Martínez-Ramírez A; Ruiz-Llorente S; Urioste M; Cigudosa JC; Benítez J
    Hum Genet; 2003 Feb; 112(2):178-85. PubMed ID: 12522559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation.
    Schmidt L; Li F; Brown RS; Berg S; Chen F; Wei MH; Tory K; Lerman I; Zbar B
    Cancer J Sci Am; 1995; 1(3):191-5. PubMed ID: 9166475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of multiple loci on chromosome 3 in renal cell cancer development.
    van den Berg A; Buys CH
    Genes Chromosomes Cancer; 1997 Jun; 19(2):59-76. PubMed ID: 9171996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma.
    Kanayama H; Lui WO; Takahashi M; Naroda T; Kedra D; Wong FK; Kuroki Y; Nakahori Y; Larsson C; Kagawa S; Teh BT
    J Med Genet; 2001 Mar; 38(3):165-70. PubMed ID: 11238683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
    Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
    Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
    Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
    Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic characterization of renal cell carcinoma in von Hippel-Lindau syndrome.
    Goodman MD; Goodman BK; Lubin MB; Braunstein G; Rotter JI; Schreck RR
    Cancer; 1990 Mar; 65(5):1150-4. PubMed ID: 2302664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
    Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
    Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement.
    Rodríguez-Perales S; Meléndez B; Gribble SM; Valle L; Carter NP; Santamaría I; Conde L; Urioste M; Benítez J; Cigudosa JC
    Hum Mol Genet; 2004 May; 13(9):983-90. PubMed ID: 15016767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential
    Mizutani K; Yokoi S; Sawada S; Sakamoto I; Kameyama K; Kamei S; Hirade K; Sugiyama S; Matsunaga K; Yamada T; Kato Y; Nishihara H; Ishihara S; Deguchi T
    Cancer Genomics Proteomics; 2022; 19(6):740-746. PubMed ID: 36316043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 3 translocations and the risk to develop renal cell cancer: a Dutch intergroup study.
    Van Erp F; Van Ravenswaaij C; Bodmer D; Eleveld M; Hoogerbrugge N; Mulders P; Geurts van Kessel A
    Genet Couns; 2003; 14(2):149-54. PubMed ID: 12872808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN.
    Woodward ER; Ricketts C; Killick P; Gad S; Morris MR; Kavalier F; Hodgson SV; Giraud S; Bressac-de Paillerets B; Chapman C; Escudier B; Latif F; Richard S; Maher ER
    Clin Cancer Res; 2008 Sep; 14(18):5925-30. PubMed ID: 18794106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21).
    Bodmer D; Eleveld M; Ligtenberg M; Weterman M; van der Meijden A; Koolen M; Hulsbergen-van der Kaa C; Smits A; Smeets D; Geurts van Kessel A
    Cancer Genet Cytogenet; 2002 Apr; 134(1):6-12. PubMed ID: 11996788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
    Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP
    Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.